Pacific Bio (NASDAQ: PACB) reported Q2 EPS of ($0.13), $0.03 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $20.6 million versus the consensus estimate of $17.2 million.

For earnings history and earnings-related data on Pacific Bio (PACB) click here.